As a result of their insulin-independent mechanism of action, SGLT-2 inhibitors can be used for monotherapy and as a component of combination therapy with other antidiabetic agents with complementary modes of action to improve glycaemic control in patients with type 2 diabetes [1,2]. Here, INS is linked to type 2 diabetes mellitus.